Survivin 2B peptide
Survivin 2B peptide (LMLGEFLKL)
9 Amino Acids · MW: 1063.4 Da
Amino Acids
9
Molecular Weight
1063.4 Da
Half-life
minutes to hours
Research Score
4.0
Studies
35
Storage
Store lyophilized at -20°C, reconstituted at 2-8°C
What is Survivin 2B peptide?
A survivin-derived HLA-A24-restricted epitope investigated as a peptide vaccine antigen. It targets survivin, a frequently overexpressed inhibitor of apoptosis in tumors.
Key Benefits & Mechanisms
targets a tumor survival protein
peptide-vaccine compatible
HLA-restricted precision immunotherapy
low direct toxicity
Research Summary
Survivin peptide vaccines have been studied in hepatocellular carcinoma, gastric cancer, lung cancer, and other malignancies. The main signal is immunogenicity, with occasional clinical responses and a strong rationale for combination immunotherapy.
Related Peptides
GV1001
Human telomerase reverse transcriptase (hTERT) 611-626 peptide GV1001
A telomerase-derived 16-mer peptide developed as a cancer vaccine antigen. It is designed to trigger T-cell responses against hTERT-expressing tumors.
Cancer ResearchNelipepimut-S
HER2/neu-derived peptide vaccine Nelipepimut-S (E75; KIFGSLAFL)
A 9-mer HLA-A2/A3-restricted peptide from HER2/neu used as a vaccine antigen. It aims to expand cytotoxic T-cell responses against HER2-positive tumors.
Cancer ResearchWT1 peptide
Wilms tumor 1 (WT1) antigen-derived peptide RMFPNAPYL
A WT1-derived 9-mer peptide used in peptide-vaccine strategies for leukemias and solid tumors. It is intended to generate HLA-restricted cytotoxic T-cell responses against WT1-positive cancer cells.
Cancer ResearchTumstatin
Collagen IV Alpha-3 NC1 Domain (Tumstatin)
Tumstatin is a collagen IV-derived fragment that inhibits angiogenesis and can induce apoptosis in endothelial cells. It is studied as a selective suppressor of pathologic vessel growth in tumor biology.
Cancer Research